Skip to NavigationSkip to content

Akorn CEO resigns after $4.3bn Fresenius deal falls through

Published on 10/12/18 at 10:07am

The CEO of American generics firm Akorn Inc has stepped down following a ruling from the Delaware Supreme Court declaring that a rapid downturn in Akorn’s business was reason enough for German company Fresenius to walk away from a $4.3 billion dollar acquisition.

Akorn announced that the CEO of the Illinois-based firm, Raj Rai was retiring from his position following the Delaware court’s decision.  Shares in Akorn fell by as much as 37%, while trading was temporarily suspended after the appeals court issued its three page ruling. Rai will remain in his post until a successor is named.

Fresenius pulled out of the deal over concerns that Akorn would not meet profit projections. The German firms decision was however settled after an anonymous whistle-blower raised concerns as to a longstanding pattern of problems in Akorn’s drug-development and manufacturing systems.  

Board chairman Alan Weinstein commented: “We recognise that this has been an extended period of uncertainty for Akorn's customers, employees and investors and the board is committed to ensuring the company’s stability and long-term growth.”

Piper Jaffray analyst, David Amsellem commented on Rai’s resignation in suggesting that Akorn, “could benefit from a new leadership team that is better versed in manufacturing operations and generics R&D.”

Matthias Link, a spokesman for Fresenius suggested that the ruling was “very welcome.”

Louis Goss

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches